

## NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

## Review Proposal Project

## Technology Appraisal no. 213; aripiprazole for the treatment of schizophrenia in people aged 15-17

## Provisional matrix of consultees and commentators

| Consultees   | Commentators (no right to submit or appeal)  |
|--|--|
| <p><u>Manufacturers/sponsors</u></p> <ul style="list-style-type: none"> <li>• Bristol Myers Squibb, Otsuka Pharmaceuticals (aripiprazole)</li> </ul> <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> <li>• Action for Sick Children</li> <li>• Afiya Trust</li> <li>• Black Health Agency</li> <li>• Changes</li> <li>• Children's Society</li> <li>• Chinese Mental Health Association</li> <li>• Chinese National Healthy Living Centre</li> <li>• Equalities National Council</li> <li>• Max Appeal</li> <li>• Mental Health Foundation</li> <li>• Mental Health Matters</li> <li>• Mental Health Providers Forum</li> <li>• Mind</li> <li>• Muslim Council of Britain</li> <li>• Muslim Health Network</li> <li>• National Children's Bureau</li> <li>• National Parent Partnership Network</li> <li>• National Perceptions Forum</li> <li>• Rethink</li> <li>• SANE</li> <li>• South Asian Health Foundation</li> <li>• Specialised Healthcare Alliance</li> <li>• Together</li> <li>• UK Advocacy Network</li> <li>• United Response</li> <li>• WellChild</li> <li>• YoungMinds</li> </ul> <p><u>Professional groups</u></p> <ul style="list-style-type: none"> <li>• Association for Young People's Health</li> </ul> | <p><u>General</u></p> <ul style="list-style-type: none"> <li>• Board of Community Health Councils in Wales</li> <li>• British National Formulary</li> <li>• Care Quality Commission</li> <li>• Commissioning Support Appraisals Service</li> <li>• Department of Health, Social Services and Public Safety for Northern Ireland</li> <li>• Hafal</li> <li>• Healthcare Improvement Scotland</li> <li>• Medicines and Healthcare products Regulatory Agency</li> <li>• MIND Cymru</li> <li>• National Association of Primary Care</li> <li>• National Mental Health Development Unit</li> <li>• National Pharmacy Association</li> <li>• NHS Alliance</li> <li>• NHS Commercial Medicines Unit</li> <li>• NHS Confederation</li> <li>• Public Health Wales NHS Trust</li> <li>• Scottish Medicines Consortium</li> </ul> <p><u>Comparator manufacturers</u></p> <ul style="list-style-type: none"> <li>• Actavis UK (risperidone)</li> <li>• AstraZeneca (quetiapine)</li> <li>• Dexcel Pharma (risperidone)</li> <li>• Eli Lilly &amp; Company (olanzapine)</li> <li>• Janssen-Cilag (risperidone)</li> <li>• Merz (clozapine)</li> <li>• Novartis Pharmaceuticals (clozapine)</li> <li>• Sandoz (risperidone)</li> <li>• Sanofi-aventis (risperidone)</li> <li>• Teva UK (clozapine)</li> </ul> |

| Consultees   | Commentators (no right to submit or appeal)   |
|--|---|
| <ul style="list-style-type: none"> <li>• British Association for Counselling and Psychotherapy</li> <li>• British Association for Psychopharmacology</li> <li>• British Association of Behavioural and Cognitive Psychotherapies</li> <li>• British Association of Psychotherapists</li> <li>• British Confederation of Psychotherapists</li> <li>• British Neuropsychiatry Association</li> <li>• British Psychological Society</li> <li>• Mental Health Nurses Association</li> <li>• Primary Care Mental Health Education</li> <li>• Royal College of General Practitioners</li> <li>• Royal College of Nursing</li> <li>• Royal College of Paediatrics and Child Health</li> <li>• Royal College of Pathologists</li> <li>• Royal College of Physicians</li> <li>• Royal College of Psychiatrists</li> <li>• Royal Society of Medicine</li> <li>• United Kingdom Clinical Pharmacy Association</li> <li>• United Kingdom Council for Psychotherapy</li> <li>• United Kingdom Psychiatric Pharmacy Group</li> </ul> <p><u>Others</u></p> <ul style="list-style-type: none"> <li>• Department of Health</li> <li>• NHS Hillingdon</li> <li>• Torbay Care NHS Trust</li> <li>• Welsh Assembly Government</li> </ul> | <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> <li>• Cochrane Schizophrenia Group</li> <li>• Institute of Psychiatry</li> <li>• MRC Clinical Trials Unit</li> <li>• National Institute for Health Research</li> <li>• National Primary Care Research &amp; Development Centre</li> </ul> <p><u>Assessment Group</u></p> <ul style="list-style-type: none"> <li>• Assessment Group tbc</li> <li>• National Institute for Health Research Health Technology Assessment Programme</li> </ul> <p><u>Associated Guideline groups</u></p> <ul style="list-style-type: none"> <li>• National Collaborating Centre for Mental Health</li> </ul> <p><u>Associated Public Health groups</u></p> <ul style="list-style-type: none"> <li>• None</li> </ul> |

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

**Definitions:**Consultees

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Assembly Government and relevant NHS organisations in England.

Consultees can participate in the consultation on the draft scope, the Assessment Report and the Appraisal Consultation Document, they are invited to prepare a submission dossier and all non-manufacturers/sponsors consultee organisations can nominate clinical specialists and patient experts to present their personal views to the Appraisal Committee. All consultees are given the opportunity to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare a submission dossier, and that receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; Healthcare Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the *British National Formulary*).

All non-manufacturers/sponsors commentator organisations can nominate clinical specialists and patient experts to present their personal views to the Appraisal Committee.

Assessment Group

An independent academic group (commissioned by the NHS Research and Development Health Technology Assessment Programme [HTA Programme] to assist in the appraisal) prepares an Assessment Report on the health technology (a review of the clinical and cost effectiveness of the technology(ies) based on a systematic review of the literature and a review of manufacturer and sponsor submission to the Institute).